You are here

  • Home
  • Archive
  • Volume 12, Issue 8
  • Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study

 

Online download statistics by month:

Online download statistics by month: August 2024 to November 2025

AbstractFullPdf
Aug 2024676678133
Sep 2024243244117
Oct 202416416497
Nov 202412012168
Dec 202412612877
Jan 202512612676
Feb 202513713876
Mar 202512212275
Apr 202514614685
May 202511111275
Jun 2025838347
Oct 2025111
Nov 2025110
Total20562064927